• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Teladoc Health, Dexcom Offers CGM-Powered Insights to People with Type 2 Diabetes

Share:

January 15, 2021

Highlights on this story:
  • Teladoc Health and Dexcom announced an expanded partnership on a new offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes at no cost.

Teladoc Health, Inc., the first and only comprehensive virtual care system, and DexCom, Inc., the leader in real-time continuous glucose monitoring (CGM), today announced that joint Livongo for Diabetes and Dexcom members will now receive CGM-powered insights. In January of 2020, Livongo, which merged with Teladoc Health in October, and Dexcom announced the first phase of their strategic relationship, a data-sharing agreement for Livongo for Diabetes members using Dexcom CGM technology.

Expanded Partnership Details

“We are excited to announce the next phase of our relationship with Teladoc Health, along with launching a commercial pilot demonstrating how Dexcom’s leading CGM combined with Teladoc Health’s data science capabilities enhance the diabetes management experience,” said Matt Dolan, senior vice president and general manager of new markets for Dexcom. “We have received powerful feedback from people with Type 2 diabetes using our technology, and through additional innovative product features, we fully anticipate that we will deliver an even greater impact.”

The expanded partnership includes two developments:

1. Enhanced product capabilities through CGM-powered insights, a new set of features and reports that help members more easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels. By combining Dexcom CGM data with additional signals from Teladoc Health, including activity data and food intake, CGM-powered insights offer members a complete health profile and recommendations that support ongoing diabetes management.

2. A pilot program demonstrating the impact of CGM-powered insights for people with Type 2 diabetes. Eligible members will receive an integrated product experience including the Livongo for Diabetes program, Dexcom CGM technology and CGM-powered insights at no cost.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Teladoc Health’s partnership with Dexcom further empowers whole person health through an innovative combination of advanced technology and human expertise,” said Amar Kendale, chief product officer of Teladoc Health. “Our focus is to offer a consumer experience that makes it easy, safe and affordable for people to manage their health with confidence. We are excited about our continued work with Dexcom and new features that enable smarter care, leading to measurable consumer behavior change and better health outcomes.”

Why It Matters

It is estimated that 463 million adults around the world live with diabetes[1], a number expected to rise to 700 million by 2045. According to the Centers for Disease Control and Prevention, regular physical activity, weight management, and improved blood pressure management are important factors for preventing diabetes-related complications[2].

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate CancerXencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
  • BurstIQ Acquires Olive AI’s Business Intelligence PlatformBurstIQ Acquires Olive AI’s Business Intelligence Platform
  • New Clinically Validated SleepCheck App LaunchesNew Clinically Validated SleepCheck App Launches
  • Fitbit And Health2Synch Partner Up For Diabetes ManagementFitbit And Health2Synch Partner Up For Diabetes Management
  • Kyruus Raises $30M to Expand Provider Search and Scheduling SolutionsKyruus Raises $30M to Expand Provider Search and Scheduling Solutions
  • Perrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth StrategyPerrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy
  • Can technology restore humanity to healthcare?Can technology restore humanity to healthcare?
  • Growing Reliance On Charity, Crowd Funding To Pay For Medical Bills Means Stressed Patients, Inequities In CareGrowing Reliance On Charity, Crowd Funding To Pay For Medical Bills Means Stressed Patients, Inequities In Care

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications